-transparent.png){kind=logo}
OBJECTIVE Children with recurrent or progressive central nervous system (CNS) tumors have an unfavorable prognosis. Based on Pediatric Oncology Group (POG) institutional pilot data, low-dose oral methotrexate (MTX) was studied. METHODS Eight dosages of MTX 7.5 mg/m2 every 6 hours were administered on a weekly schedule for as long as 18 months. Patients in six different brain tumor strata were accrued. RESULTS The response rates (complete or partial responses) were as follows: astrocytoma 2 of 10, malignant glioma 1 of 19, medulloblastoma 0 of 18, brainstem tumor 0 of 12, ependymoma 1 of 7, and miscellaneous histologic types 0 of 12. The main toxicities, mucositis, myelosuppression, and hepatic transaminase elevation were considered tolerable. CONCLUSIONS Low-dose oral MTX showed no significant activity against malignant glioma, medulloblastoma, brainstem tumors, and miscellaneous histologic types. Indeterminate but low response rates were observed in children with astrocytoma and ependymoma. This regimen will not be recommended for front-line therapy.
A F Mulne, and
J M Ducore, and
R D Elterman, and
H S Friedman, and
J P Krischer, and
L E Kun, and
J J Shuster, and
R P Kadota
October 1985,
Cancer,
A F Mulne, and
J M Ducore, and
R D Elterman, and
H S Friedman, and
J P Krischer, and
L E Kun, and
J J Shuster, and
R P Kadota
February 1992,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A F Mulne, and
J M Ducore, and
R D Elterman, and
H S Friedman, and
J P Krischer, and
L E Kun, and
J J Shuster, and
R P Kadota
February 1996,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A F Mulne, and
J M Ducore, and
R D Elterman, and
H S Friedman, and
J P Krischer, and
L E Kun, and
J J Shuster, and
R P Kadota
August 2001,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A F Mulne, and
J M Ducore, and
R D Elterman, and
H S Friedman, and
J P Krischer, and
L E Kun, and
J J Shuster, and
R P Kadota
November 1990,
Investigational new drugs,
A F Mulne, and
J M Ducore, and
R D Elterman, and
H S Friedman, and
J P Krischer, and
L E Kun, and
J J Shuster, and
R P Kadota
August 1988,
International journal of radiation oncology, biology, physics,
A F Mulne, and
J M Ducore, and
R D Elterman, and
H S Friedman, and
J P Krischer, and
L E Kun, and
J J Shuster, and
R P Kadota
October 2003,
Neuro-oncology,
A F Mulne, and
J M Ducore, and
R D Elterman, and
H S Friedman, and
J P Krischer, and
L E Kun, and
J J Shuster, and
R P Kadota
January 1998,
Journal of pediatric hematology/oncology,
A F Mulne, and
J M Ducore, and
R D Elterman, and
H S Friedman, and
J P Krischer, and
L E Kun, and
J J Shuster, and
R P Kadota
July 1992,
Investigational new drugs,
A F Mulne, and
J M Ducore, and
R D Elterman, and
H S Friedman, and
J P Krischer, and
L E Kun, and
J J Shuster, and
R P Kadota
November 2001,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
